Arca
Skip to content
Tools
Tools

PTK6: Protein-tyrosine kinase 6

Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on PTK6, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Vandetanib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        VandetanibBoxed warningApprovedSanofiSmall moleculeInhibitorTyrosine-protein kinase BRK inhibitor3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
        Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerVandetanibPhase 2RecruitingWest China HospitalJul 1, 2024
        A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerVandetanibPhase 3Active, not recruitingLoxo Oncology, Inc.Dec 26, 2019
        SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerVandetanibPhase 2Active, not recruitingUNICANCERNov 24, 2014

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Medullary thyroid gland carcinoma
        0.59
        Non-small cell lung carcinoma
        0.46
        Thyroid gland carcinoma
        0.44
        Neoplasm
        0.40
        Colorectal adenocarcinoma
        0.38
        Skin basal cell carcinoma
        0.37
        Thyroid tumor
        0.37
        Endometrial endometrioid adenocarcinoma
        0.37
        Gastric carcinoma
        0.37
        Breast carcinoma
        0.31

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4601, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q13882, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.